- ►annals.org LE Levesque, JM Brophy, B Zhang - Annals of internal medicine, 2005 - Am Coll Physicians Background: Cyclooxygenase-2 (COX-2) selective inhibitors have been marketed
since 1999 as safer alternatives to nonsteroidal anti-inflammatory drugs
(NSAIDs). Debate about their cardiac safety has culminated in the recent ... Cited by 193 - Related articles - All 15 versions
- ►annals.org SE Kimmel, JA Berlin, M Reilly, J Jaskowiak, L … - Annals of internal medicine, 2005 - Am Coll Physicians Background: Studies have postulated that cyclooxygenase-2 (COX-2) selective
inhibitors affect cardiovascular risk through various mechanisms. Some of these
mechanisms could increase risk (for example, inhibition of prostacyclin ... Cited by 197 - Related articles - All 15 versions
SP Johnsen, H Larsson, RE Tarone, JK … - Archives of Internal Medicine, 2005 - archinte.highwire.org Methods Using data from hospital discharge registries in the counties of North
Jutland, Viborg, and Aarhus, Denmark, and the Danish Civil Registration System,
we identified 10 280 cases of first-time hospitalization for MI and 102 797 ... Cited by 193 - Related articles - All 7 versions
N Exposure - acponline.org Background: Cyclooxygenase-2 (COX-2) selective inhibitors have been marketed
since 1999 as safer alternatives to nonsteroidal anti-inflammatory drugs
(NSAIDs). Debate about their cardiac safety has culminated in the recent ... Related articles - Cached - All 2 versions
- ►mt.gov [PDF] DJ Graham, D Campen, R Hui, M Spence, C … - The Lancet, 2005 - Elsevier We used data from Kaiser Permanente in California to assemble a cohort of all
patients age 18–84 years treated with a NSAID between Jan 1, 1999, and Dec 31,
2001, within which we did a nested case-control study. Cases of serious ... Cited by 537 - Related articles - All 33 versions
- ►ahajournals.org DH Solomon, S Schneeweiss, RJ Glynn, Y … - Circulation, 2004 - Am Heart Assoc Methods and Results— We conducted a matched case-control study of 54 475
patients 65 years of age or older who received their medications through 2
state-sponsored pharmaceutical benefits programs in the United States. All ... Cited by 445 - Related articles - BL Direct - All 14 versions
M Mamdani, P Rochon, DN Juurlink, GM … - Archives of Internal Medicine, 2003 - archinte.highwire.org Methods We conducted a population-based retrospective cohort study using
administrative health care data from Ontario, Canada, from April 1, 1998, to
March 31, 2001. We identified NSAID-naive cohorts of subjects aged 66 years ... Cited by 252 - Related articles - BL Direct - All 7 versions
- ►bmj.com J Hippisley-Cox, C Coupland - British Medical Journal, 2005 - bmj.com Aims To determine the comparative risk of myocardial infarction in patients
taking cyclo-oxygenase-2 and other non-steroidal anti-inflammatory drugs
(NSAIDs) in primary care between 2000 and 2004; to determine these risks in ... Cited by 325 - Related articles - All 14 versions
WA Ray, CM Stein, JR Daugherty, K Hall, PG … - The Lancet, 2002 - Elsevier Results of premarketing and postmarketing trials have raised doubts about the
cardiovascular safety of the non-steroidal anti-inflammatory drug (NSAID)
rofecoxib, especially at doses greater than 25 mg. Between Jan 1, 1999, and ... Cited by 437 - Related articles - All 9 versions
FT Shaya, SW Blume, CM Blanchette, MR Weir … - Archives of Internal Medicine, 2005 - archinte.highwire.org Background The differential effects of selective cyclooxygenase-2 (COX-2)
inhibitors compared with nonspecific nonsteroidal anti-inflammatory agents
(NSAIDs) on platelet aggregation and prostacyclin/thromboxane balance have ... Cited by 61 - Related articles - All 8 versions
